|
|
|
HPV-003
|
Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With Cellectra-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18. |
II |
Immunotherapy |
Not Applicable |
|
Onconova 09-09
|
A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma |
II |
Signal Transduction Inhibitor |
rigosertib |
|
CLDE225A2112
|
A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors |
I |
Other |
warfarin; bupropion |
|
CA186-011
|
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors |
I |
Immunotherapy |
BMS-663513 |